☆ 4.5 Editorial Material

Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations

GENE THERAPY (2017)

期刊

GENE THERAPY

卷 24, 期 9, 页码 539-541

出版社

NATURE PUBLISHING GROUP

DOI: 10.1038/gt.2017.79

关键词

-

类别

Biochemistry & Molecular Biology Biotechnology & Applied Microbiology Genetics & Heredity Medicine, Research & Experimental

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Genetics & Heredity

Case Report: Whole-Exome Sequencing With MLPA Revealed Variants in Two Genes in a Patient With Combined Manifestations of Spinal Muscular Atrophy and Duchenne Muscular Dystrophy

Yu Xia, Yijie Feng, Lu Xu, Xiaoyang Chen, Feng Gao, Shanshan Mao

Summary: Spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD) are common neuromuscular disorders with similar clinical manifestations caused by mutations in different genes. This case report highlights a Chinese family presenting with symptoms of both SMA and DMD, with genetic testing revealing homozygous deletions in SMN1 gene exons 7 and 8, as well as a deletion in DMD gene exon 50. The use of whole-exome sequencing (WES) and multiplex ligation-dependent probe amplification (MLPA) in diagnosis underscores the importance of genetic testing methods in distinguishing between neuromuscular diseases.

FRONTIERS IN GENETICS (2021)

添加到收藏夹

Article Clinical Neurology

Child Neurology: Pathologically Confirmed Thrombotic Microangiopathy Caused by Onasemnogene Abeparvovec Treatment for SMA

Kotaro Yazaki, Satoru Sakuma, Norikatsu Hikita, Rika Fujimaru, Takashi Hamazaki

Summary: This article presents the renal histopathologic findings of drug-induced thrombotic microangiopathy (TMA) due to onasemnogene abeparvovec. The patient's TMA resolved after receiving treatment.

NEUROLOGY (2022)

添加到收藏夹

Article Pathology

Cytochemical Characterization of Cerebrospinal Fluid Macrophage Inclusions in Pediatric Patients Receiving Intrathecal Nusinersen (SPINRAZA®) for Spinal Muscular Atrophy

Kristian T. Schafernak, Jeffrey R. Jacobsen, Dulce Hernandez, Robin D. Kaye, Sylvia E. Perez

Summary: Cytology specimens from SMA patients receiving nusinersen revealed macrophages with peculiar inclusions (nusinophages), a finding previously reported mainly in adults with SMA types 2 and 3. This highlights the importance for cytotechnologists and cytopathologists to be aware of these inclusions to avoid misinterpretation, especially with the increasing use of oligonucleotide therapy in various conditions.

ACTA CYTOLOGICA (2022)

添加到收藏夹

Article Clinical Neurology

Quality of Life in SMA Patients Under Treatment With Nusinersen

Lucas Mix, Benedikt Winter, Claudia D. Wurster, Sophia Platen, Simon Witzel, Zeljko Uzelac, Heiko Graf, Albert C. Ludolph, Dorothee Lule

Summary: Despite severe physical restrictions, SMA patients reported high levels of QoL and low levels of depressiveness at study entry. Early disease onset and low levels of physical functioning were associated with better gQoL and lower levels of depressiveness. A significant decrease of gQoL in patients was evident over the course of the study, while adult patients reported a significant increase in perceived health.

FRONTIERS IN NEUROLOGY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Identification of Novel CSF-Derived miRNAs in Treated Paediatric Onset Spinal Muscular Atrophy: An Exploratory Study

Arlene M. D'Silva, Didu Kariyawasam, Pooja Venkat, Chelsea Mayoh, Michelle A. A. Farrar

Summary: The search for clinically significant biomarkers that provide insight into disease progression and therapeutic response is crucial for spinal muscular atrophy (SMA) disease modifying therapies. In this study, miRNA-sequencing was used to identify differential miRNA expression in the cerebrospinal fluid (CSF) of six SMA children treated with nusinersen. Fourteen differentially expressed miRNAs were significantly altered during nusinersen treatment, with miR-7-5p, miR-15a-5p, miR-15b-3p/5p, miR-126-5p, miR-128-2-5p, and miR-130a-3p showing the greatest magnitude of change. The study also identified the mammalian target of rapamycin and mitogen-activated protein kinase signaling pathways as being important.

PHARMACEUTICS (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

High Concentration of an ISS-N1-Targeting Antisense Oligonucleotide Causes Massive Perturbation of the Transcriptome

Eric William Ottesen, Diou Luo, Natalia Nikolaevna Singh, Ravindra Narayan Singh

Summary: The intronic splicing silencer N1 (ISS-N1) within Survival Motor Neuron 2 (SMN2) intron 7 is a therapeutic target for treating spinal muscular atrophy. Treatment with 100 nM of Anti-N1 resulted in substantial stimulation of SMN2 exon 7 inclusion but also caused significant perturbations in the transcriptome and widespread aberrant splicing. Shorter ISS-N1-targeting ASOs showed a substantial reduction in off-target effects, providing important insights for better ASO design and dosing regimens of ASO-based drugs.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Genetics & Heredity

The incidence of hydrocephalus among patients with and without spinal muscular atrophy (SMA): Results from a US electronic health records study

Emma Viscidi, Nasha Wang, Maneesh Juneja, Ishir Bhan, Claudia Prada, Dayle James, Stacie Lallier, Corinne Makepeace, Karen Laird, Susan Eaton, Anne Dilley, Susan Hall

Summary: This retrospective analysis using US EHR data found that SMA patients had an approximately fourfold increased risk of hydrocephalus compared with non-SMA controls in the era preceding nusinersen treatment. It suggests the importance of properly evaluating adverse events in nusinersen-treated SMA patients.

ORPHANET JOURNAL OF RARE DISEASES (2021)

添加到收藏夹

Article Clinical Neurology

Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen

V. A. Sansone, G. Coratti, M. C. Pera, M. Pane, S. Messina, F. Salmin, E. Albamonte, R. De Sanctis, M. Sframeli, V Di Bella, S. Morando, A. D'Amico, A. L. Frongia, L. Antonaci, A. Pirola, M. Pedemonte, E. Bertini, C. Bruno, E. Mercuri

Summary: The study compared demographics and disease characteristics between regularly followed SMA patients and newcomers, revealing differences in motor and respiratory function, particularly a higher proportion of newcomers at the severe end of the spectrum in type II patients. Only approximately a third of newcomers initiated treatment, compared to 51% of the regularly followed patients. Identification of patients not part of registries will help redefine the overall prevalence of SMA and different phenotypes.

EUROPEAN JOURNAL OF NEUROLOGY (2021)

添加到收藏夹

Article Medicine, Research & Experimental

PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice

Anna J. Kordala, Jessica Stoodley, Nina Ahlskog, Muhammad Hanifi, Antonio Garcia Guerra, Amarjit Bhomra, Wooi Fang Lim, Lyndsay M. Murray, Kevin Talbot, Suzan M. Hammond, Matthew J. A. Wood, Carlo Rinaldi

Summary: Spinal muscular atrophy (SMA) is an important genetic cause of infant mortality. The discovery of PRMT inhibitor MS023 shows promising potential for treating SMA and improving the disease phenotype, especially when combined with nusinersen. Further clinical investigation of PRMT inhibition as a standalone or add-on therapy for SMA is warranted.

EMBO MOLECULAR MEDICINE (2023)

添加到收藏夹

Article Clinical Neurology

Nusinersen in adult patients with 5q spinal muscular atrophy: A multicenter observational cohorts' study

Juan F. Vazquez-Costa, Monica Povedano, Andres E. Nascimiento-Osorio, Antonio Moreno Escribano, Solange Kapetanovic Garcia, Raul Dominguez, Jessica M. Exposito, Laura Gonzalez, Carla Marco, Julita Medina Castillo, Nuria Muelas, Daniel Natera de Benito, Nancy Carolina Nungo Garzon, Inmaculada Pitarch Castellano, Teresa Sevilla, David Hervas

Summary: The study assessed the safety and efficacy of nusinersen in adult SMA patients, finding significant improvements in multiple motor scales in the treated group, with most patients experiencing some degree of improvement with treatment. However, the most severely affected patients with complex spines may have a less favorable risk-benefit ratio.

EUROPEAN JOURNAL OF NEUROLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy

Juan F. Vazquez-Costa, Monica Povedano, Andres E. Nascimiento-Osorio, Antonio Moreno Escribano, Solange Kapetanovic Garcia, Raul Dominguez, Jessica M. Exposito, Laura Gonzalez, Carla Marco, Julita Medina Castillo, Nuria Muelas, Daniel Natera de Benito, Nancy Carolina Nungo Garzon, Inmaculada Pitarch Castellano, Teresa Sevilla, David Hervas

Summary: This study evaluated the validity and limitations of assessment scales for adult SMA patients, finding that bedside functional scales have some advantages but limited responsiveness.

EUROPEAN JOURNAL OF NEUROLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Nusinersen Treatment of Children with Later-Onset Spinal Muscular Atrophy and Scoliosis Is Associated with Improvements or Stabilization of Motor Function

Sally Dunaway Young, Jacqueline Montes, Allan M. Glanzman, Richard Gee, John W. Day, Richard S. Finkel, Basil T. Darras, Darryl C. De Vivo, Giulia Gambino, Richard Foster, Janice Wong, Steve Garafalo, Zdenek Berger

Summary: Nusinersen treatment can improve or stabilize motor function in non-ambulatory children with later-onset spinal muscular atrophy (SMA). The severity of baseline scoliosis is associated with later motor function, with greater decline in motor function observed in children with more severe scoliosis.

JOURNAL OF CLINICAL MEDICINE (2023)

添加到收藏夹

Article Medicine, General & Internal

Cerebrospinal Fluid Proteomic Changes after Nusinersen in Patients with Spinal Muscular Atrophy

Marie Beaudin, Tahereh Kamali, Whitney Tang, Katharine A. Hagerman, Sally Dunaway Young, Lisa Ghiglieri, Dana M. Parker, Benoit Lehallier, Carolina Tesi-Rocha, Jacinda B. Sampson, Tina Duong, John W. Day

Summary: This study explored the therapeutic pathways and predictors of motor improvement in spinal muscular atrophy (SMA) patients treated with nusinersen through a proteomic analysis of their cerebrospinal fluid (CSF). The study identified certain proteins using a machine learning algorithm that were predictive of motor improvement after 2 years of treatment. These findings highlight the potential application of CSF biomarkers in predicting treatment response in SMA patients.

JOURNAL OF CLINICAL MEDICINE (2023)

添加到收藏夹

Review Pediatrics

Adverse events in the treatment of spinal muscular atrophy in children and adolescents with nusinersen: A systematic review and meta-analysis

Zhi-Juan Zhong, Pi-Mei Zheng, Hui-Hong Dou, Ji-Gan Wang

Summary: This study aimed to systematically analyze adverse events (AEs) in the treatment of spinal muscular atrophy (SMA) with Nusinersen in children and adolescents. The study found that Nusinersen-related AEs were rare and it effectively reduced common, serious, and fatal AEs in children and adolescents with SMA.

FRONTIERS IN PEDIATRICS (2023)

添加到收藏夹

Article Neurosciences

Total tau in cerebrospinal fluid detects treatment responders among spinal muscular atrophy types 1-3 patients treated with nusinersen

Goran Simic, Vana Vukic, Marija Babic, Maria Banovic, Ivana Berecic, Ena Spanic, Klara Zubcic, Anja Tea Golubic, Marija Barisic Kutija, Ana Merkler Sorgic, Zeljka Vogrinc, Ivan Lehman, Patrick R. Hof, Jadranka Sertic, Nina Barisic

Summary: This study aimed to identify reliable markers for monitoring treatment response and predicting treatment outcomes in patients with spinal muscular atrophy (SMA). The main finding was that the concentration of total tau protein in cerebrospinal fluid (CSF) correlated significantly with the duration of nusinersen treatment and motor improvement in SMA patients. The measurement of total tau concentration in CSF can serve as a reliable index for monitoring biomarker and clinical response to nusinersen therapy in SMA patients.

CNS NEUROSCIENCE & THERAPEUTICS (2022)

添加到收藏夹

Article Medicine, General & Internal

A model-based economic evaluation of four newborn screening strategies for cystic fibrosis in Flanders, Belgium

Masja Schmidt, Amber Werbrouck, Nick Verhaeghe, Elke De Wachter, Steven Simoens, Lieven Annemans, Koen Putman

ACTA CLINICA BELGICA (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US

Chiara Whichello, Eline van Overbeeke, Rosanne Janssens, Karin Scholin Bywall, Selena Russo, Jorien Veldwijk, Irina Cleemput, Juhaeri Juhaeri, Bennett Levitan, Juergen Kuebler, Meredith Smith, Richard Hermann, Matthias Englbrecht, Axel J. Hueber, Alina Comanescu, Sarah Harding, Steven Simoens, Isabelle Huys, Esther W. de Bekker-Grob

FRONTIERS IN PHARMACOLOGY (2019)

添加到收藏夹

Review Medical Informatics

Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review

Rosanne Janssens, Isabelle Huys, Eline van Overbeeke, Chiara Whichello, Sarah Harding, Juergen Kuebler, Juhaeri Juhaeri, Antonio Ciaglia, Steven Simoens, Hilde Stevens, Meredith Smith, Bennett Levitan, Irina Cleemput, Esther de Bekker-Grob, Jorien Veldwijk

BMC MEDICAL INFORMATICS AND DECISION MAKING (2019)

添加到收藏夹

Article Public, Environmental & Occupational Health

Cost-utility analysis of lifestyle interventions to prevent type 2 diabetes in women with prior gestational diabetes

Amber Werbrouck, Masja Schmidt, Koen Putman, Lieven Annemans, Katrien Benhalima, Steven Simoens, Nick Verhaeghe

EUROPEAN JOURNAL OF PUBLIC HEALTH (2020)

添加到收藏夹

Review Economics

Universal Mental Health Interventions for Children and Adolescents: A Systematic Review of Health Economic Evaluations

Masja Schmidt, Amber Werbrouck, Nick Verhaeghe, Koen Putman, Steven Simoens, Lieven Annemans

APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2020)

添加到收藏夹

Review Economics

Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab

Caridad Pontes, Corinne Zara, Josep Torrent-Farnell, Merce Obach, Cristina Nadal, Patricia Vella-Bonanno, Michael Ermisch, Steven Simoens, Renata Curi Hauegen, Jolanta Gulbinovic, Angela Timoney, Antony P. Martin, Tanja Mueller, Anna Nachtnebel, Stephen Campbell, Gisbert Selke, Tomasz Bochenek, Celia C. Rothe, Ileana Mardare, Marion Bennie, Jurij Furst, Rickard E. Malmstrom, Brian Godman

APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2020)

添加到收藏夹

Review Oncology

Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!

Binita Dutta, Isabelle Huys, Arnold G. Vulto, Steven Simoens

BIODRUGS (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

HoUng Kim, Rieke Alten, Luisa Avedano, Axel Dignass, Fernando Gomollon, Kay Greveson, Jonas Halfvarson, Peter M. Irving, Jorgen Jahnsen, Peter L. Lakatos, JongHyuk Lee, Souzi Makri, Ben Parker, Laurent Peyrin-Biroulet, Stefan Schreiber, Steven Simoens, Rene Westhovens, Silvio Danese, Ji Hoon Jeong

DRUGS (2020)

添加到收藏夹

Article Chemistry, Medicinal

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany

Evelien Moorkens, Teresa Barcina Lacosta, Arnold G. Vulto, Martin Schulz, Gabriele Gradl, Salka Enners, Gisbert Selke, Isabelle Huys, Steven Simoens

PHARMACEUTICALS (2020)

添加到收藏夹

Review Chemistry, Medicinal

Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review

Arnold G. Vulto, Jackie Vanderpuye-Orgle, Martin van der Graaff, Steven R. A. Simoens, Lorenzo Dagna, Richard Macaulay, Beenish Majeed, Jeffrey Lemay, Jane Hippenmeyer, Sebastian Gonzalez-McQuire

PHARMACEUTICALS (2020)

添加到收藏夹

Review Chemistry, Medicinal

Informing Patients about Biosimilar Medicines: The Role of European Patient Associations

Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto, Isabelle Huys

Summary: Biosimilar medicines support national healthcare systems by reducing costs through competition, but patient knowledge and trust in biosimilars in Europe has been lacking. Informing patients with understandable, positive, transparent, tailored information, supported by audiovisual materials, is crucial for successful adoption. Collaborative efforts among stakeholders are essential for disseminating accurate information to patients.

PHARMACEUTICALS (2021)

添加到收藏夹

Article Chemistry, Medicinal

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study

Steven Simoens, Arnold G. Vulto, Pieter Dylst

Summary: This study aimed to compare drug costs and healthcare costs of intravenous biosimilar trastuzumab vs. subcutaneous reference trastuzumab in the treatment of HER2-positive breast cancer. The results showed that when considering healthcare professional time and consumables, the healthcare costs for both treatment options were similar.

PHARMACEUTICALS (2021)

添加到收藏夹

Article Chemistry, Medicinal

Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices

Liese Barbier, Steven Simoens, Caroline Soontjens, Barbara Claus, Arnold G. Vulto, Isabelle Huys

Summary: This study aims to explore the design and implementation of tender procedures for off-patent biologicals and biosimilars in Europe, identify learnings for sustainable tender approaches, and formulate recommendations. Results suggest the need to adjust tender procedures for off-patent biologicals and biosimilars, considering a more long-term strategic and market sustainable view.

PHARMACEUTICALS (2021)

添加到收藏夹

Editorial Material Chemistry, Medicinal

Emerging Insights into European Markets of Biologics, Including Biosimilars

Steven Simoens, Isabelle Huys

PHARMACEUTICALS (2022)

添加到收藏夹

Review Environmental Sciences

A Systematic Review of the Value Assessment Frameworks Used within Health Technology Assessment of Omics Technologies and Their Actual Adoption from HTA Agencies

Ilda Hoxhaj, Laurenz Govaerts, Steven Simoens, Walter Van Dyck, Isabelle Huys, Inaki Gutierrez-Ibarluzea, Stefania Boccia

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2020)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.